Technical Analysis for FOLD - Amicus Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 12.26 | 0.70% | 0.09 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | 0.70% | |
Crossed Above 200 DMA | Bullish | 0.70% | |
Crossed Above 50 DMA | Bullish | 0.70% | |
MACD Bullish Signal Line Cross | Bullish | 0.70% | |
Expansion Pivot Buy Setup | Bullish Swing Setup | 0.70% | |
Pocket Pivot | Bullish Swing Setup | 0.70% | |
Up 3 Days in a Row | Strength | 0.70% | |
Up 4 Days in a Row | Strength | 0.70% | |
50 DMA Resistance | Bearish | 7.59% | |
Outside Day | Range Expansion | 7.59% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Up 1% | about 3 hours ago |
Expansion Pivot Buy Entry | about 4 hours ago |
Rose Above Previous Day's High | about 4 hours ago |
Down 1% | about 4 hours ago |
Up 5% | 3 days ago |
Get a Trading Sidekick!
- Earnings date: 05/10/2023
Amicus Therapeutics, Inc. Description
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs known as pharmacological chaperones. It develops pharmacological chaperones as next-generation medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders. The company's development programs include small molecules as monotherapy treatments for Fabry and other lysosomal storage diseases, and enzyme replacement therapy (ERT). Its chaperone-advanced replacement therapy programs comprise chaperones co-administered with currently marketed ERTs, as well as proprietary therapeutic enzymes co-formulated with pharmacological chaperones as next-generation ERTs. The company's primary product includes migalastat HCl, a product candidate for Fabry disease that is in Phase III global registration studies for patients with genetic mutations. Its products also comprise AT2220, which has completed Phase II safety used for the treatment of Pompe disease; and AT3375 and afegostat tartrate that are in preclinical studies used for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Rare Diseases Enzymes Orphan Drug Inborn Errors Of Metabolism Lipid Storage Disorders Orphan Disease Enzyme Replacement Therapy Fabry Disease Lysosomal Storage Disorder Gaucher Disease Lysosomal Storage Disorders Pompe Disease Rare And Orphan Diseases
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 13.84 |
52 Week Low | 7.78 |
Average Volume | 1,886,247 |
200-Day Moving Average | 11.63 |
50-Day Moving Average | 11.46 |
20-Day Moving Average | 11.55 |
10-Day Moving Average | 11.54 |
Average True Range | 0.47 |
RSI (14) | 59.84 |
ADX | 15.73 |
+DI | 26.35 |
-DI | 19.77 |
Chandelier Exit (Long, 3 ATRs) | 11.07 |
Chandelier Exit (Short, 3 ATRs) | 11.97 |
Upper Bollinger Bands | 12.39 |
Lower Bollinger Band | 10.72 |
Percent B (%b) | 0.87 |
BandWidth | 14.42 |
MACD Line | -0.01 |
MACD Signal Line | -0.04 |
MACD Histogram | 0.0296 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 13.36 | ||||
Resistance 3 (R3) | 13.24 | 12.72 | 13.16 | ||
Resistance 2 (R2) | 12.72 | 12.41 | 12.78 | 13.10 | |
Resistance 1 (R1) | 12.44 | 12.23 | 12.58 | 12.57 | 13.03 |
Pivot Point | 11.92 | 11.92 | 11.99 | 11.98 | 11.92 |
Support 1 (S1) | 11.65 | 11.62 | 11.79 | 11.77 | 11.31 |
Support 2 (S2) | 11.13 | 11.43 | 11.19 | 11.24 | |
Support 3 (S3) | 10.85 | 11.13 | 11.18 | ||
Support 4 (S4) | 10.98 |